Free Trial
NASDAQ:ATXS

Astria Therapeutics Q2 2025 Earnings Report

Astria Therapeutics logo
$6.79 +0.44 (+6.93%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$6.88 +0.09 (+1.27%)
As of 08/22/2025 06:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Astria Therapeutics EPS Results

Actual EPS
-$0.57
Consensus EPS
-$0.61
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A

Astria Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$16.00 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Astria Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 12, 2025
Conference Call Time
7:00AM ET

Astria Therapeutics Earnings Headlines

Equities Analysts Set Expectations for ATXS Q3 Earnings
BONUS GUIDE - Ben Stein Prepares For the Next Financial Crisis
With inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist Ben Stein—drawing on insights from his own experience and his father’s time advising two U.S. presidents—just released a new report on how to help protect your retirement from the next major crisis.tc pixel
Q3 EPS Forecast for Astria Therapeutics Raised by Analyst
See More Astria Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Astria Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Astria Therapeutics and other key companies, straight to your email.

About Astria Therapeutics

Astria Therapeutics (NASDAQ:ATXS), a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

View Astria Therapeutics Profile

More Earnings Resources from MarketBeat